Trial Profile
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Ramucirumab (Primary) ; Lanreotide; Octreotide
- Indications Carcinoid tumour
- Focus Therapeutic Use
- 14 Apr 2022 Planned End Date changed from 1 Dec 2024 to 31 Dec 2024.
- 14 Apr 2022 Planned primary completion date changed from 1 Dec 2021 to 31 Dec 2022.
- 13 Jul 2021 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.